Genomes and Genes
Summary: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE, CONGESTIVE) or several forms of CARDIOMYOPATHIES.
Publications348 found, 100 shown here
- MicroRNA-133 controls cardiac hypertrophyAlessandra Carè
Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore Sanita, 00161 Rome, Italy
Nat Med 13:613-8. 2007..Our data show that miR-133, and possibly miR-1, are key regulators of cardiac hypertrophy, suggesting their therapeutic application in heart disease...
- Regulation of cardiac hypertrophy by intracellular signalling pathwaysJoerg Heineke
Department of Pediatrics, University of Cincinnati, Children s Hospital Medical Center, Division of Molecular Cardiovascular Biology, 3333 Burnet Ave, Cincinnati, Ohio 45229, USA
Nat Rev Mol Cell Biol 7:589-600. 2006..Recent findings in genetically modified animal models implicate important intermediate signal-transduction pathways in the coordination of heart growth following physiological and pathological stimulation...
- The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stressAtsuko Nakai
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita Osaka 565 0871, Japan
Nat Med 13:619-24. 2007....
- MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in miceThomas E Callis
Carolina Cardiovascular Biology Center, University of North Carolina, Chapel Hill, North Carolina, USA
J Clin Invest 119:2772-86. 2009..Together, our studies uncover what we believe are novel miRNA-dependent mechanisms that modulate cardiac hypertrophy and electrical conduction...
- A calcineurin-dependent transcriptional pathway for cardiac hypertrophyJ D Molkentin
Department of Molecular Biology and Oncology, The University of Texas Southwestern Medical Center at Dallas, 75225 9148, USA
Cell 93:215-28. 1998..Pharmacologic inhibition of calcineurin activity blocks hypertrophy in vivo and in vitro. These results define a novel hypertrophic signaling pathway and suggest pharmacologic approaches to prevent cardiac hypertrophy and heart failure...
- MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy?Yunhui Cheng
Cardiovascular Research Laboratory, Vascular Biology Center and Department of Surgery, University of Tennessee Health Science Center, 956 Court Avenue, Memphis, TN 38163, USA
Am J Pathol 170:1831-40. 2007..miRNAs might be a new therapeutic target for cardiovascular diseases involving cardiac hypertrophy such as hypertension, ischemic heart disease, valvular diseases, and endocrine disorders...
- Cardiac hypertrophy: the good, the bad, and the uglyN Frey
Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9148, USA
Annu Rev Physiol 65:45-79. 2003..In this review, we summarize recent insights into hypertrophic signaling and consider several novel antihypertrophic strategies...
- Cardiac plasticityJoseph A Hill
Donald W Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX 75390 8573, USA
N Engl J Med 358:1370-80. 2008
- MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genesSadakatsu Ikeda
Department of Cardiology, Children s Hospital Boston, Department of Genetics, Harvard Medical School, Boston, Massachusetts 021151, USA
Mol Cell Biol 29:2193-204. 2009..Our data indicate that miR-1 regulates cardiomyocyte growth responses by negatively regulating the calcium signaling components calmodulin, Mef2a, and Gata4...
- Activating transcription factor 3 deficiency promotes cardiac hypertrophy, dysfunction, and fibrosis induced by pressure overloadHeng Zhou
Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China
PLoS ONE 6:e26744. 2011..Our results suggested that ATF3 plays a crucial role in the development of cardiac hypertrophy via negative regulation of the MEK-ERK1/2 and JNK pathways...
- Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophyChun Li Zhang
Department of Molecular Biology, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas 75390, USA
Cell 110:479-88. 2002..mice lacking the class II HDAC, HDAC9, are sensitized to hypertrophic signals and exhibit stress-dependent cardiomegaly. Thus, class II HDACs act as signal-responsive suppressors of the transcriptional program governing cardiac ..
- Control of stress-dependent cardiac growth and gene expression by a microRNAEva van Rooij
Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390 9148, USA
Science 316:575-9. 2007..Thus, the alphaMHC gene, in addition to encoding a major cardiac contractile protein, regulates cardiac growth and gene expression in response to stress and hormonal signaling through miR-208...
- Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategiesBianca C Bernardo
Cardiac Hypertrophy Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Australia
Pharmacol Ther 128:191-227. 2010..Finally, we explore how knowledge of molecular mechanisms underlying pathological and physiological hypertrophy may influence therapeutic strategies for the treatment of cardiovascular disease and heart failure...
- Oxidative stress and cardiac hypertrophy: a reviewSubir Kumar Maulik
Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India
Toxicol Mech Methods 22:359-66. 2012..All these evidences strongly provide support to beneficial role of drugs which selectively interfere with the generation of free radicals or augment endogenous antioxidants in cardiac hypertrophy...
- Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophyIchiro Manabe
Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan
Circ Res 91:1103-13. 2002..A particular focus is the recent progress toward our understanding of the transcriptional regulatory mechanisms involved...
- Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in ratsGiselle C Melendez
Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, SC 29208, USA
Hypertension 56:225-31. 2010..These novel observations demonstrate that IL-6 induces a myocardial phenotype almost identical to that of the hypertensive heart, identifying IL-6 as potentially important in this remodeling process...
- Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodelingQinghang Liu
Department of Physiology and Biophysics, University of Washington, Seattle, USA
Circ Res 110:1077-86. 2012....
- MicroRNAs: novel regulators in cardiac development and diseaseThomas Thum
Medizinische Klinik und Poliklinik I, Universitatsklinikum, Julius Maximilians Universitat, Josef Schneider Street 2, D 97080 Wurzburg, Germany
Cardiovasc Res 79:562-70. 2008..Finally, we focus on the development and use of miRNA antagonists (antagomirs) to target miRNAs in vivo, which may translate into novel therapeutic strategies for heart disease in the future...
- An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophyPeiyong Zhai
Cardiovascular Research Institute, Department of Cell Biology and Molecular Medicine, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark 07103, USA
Circ Res 99:528-36. 2006..The YIPP motif in the AT(1)R plays an important role in mediating cardiac hypertrophy in vivo...
- Role of oxidative stress in myocardial hypertrophy and failureDouglas B Sawyer
Cardiovascular Medicine Section, Department of Medicine, Boston, MA, USA
J Mol Cell Cardiol 34:379-88. 2002
- Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanismsStefan Hein
Kerckhoff Clinic, Department of Thoracic and Cardiovascular Surgery, Bad Nauheim, Germany
Circulation 107:984-91. 2003....
- Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosisKen ichiro Okada
Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
Circulation 110:705-12. 2004..The ER responds to stress by upregulating ER chaperones, but prolonged and/or excess ER stress leads to apoptosis. However, the potential role of ER stress in pathophysiological hearts remains unclear...
- TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin IIJo El J Schultz
Department of Molecular Genetics, Biochemistry, and Microbiology, Cincinnati College of Medicine, 231 Albert Sabin Way, ML 0575, Cincinnati, OH 45267, USA
J Clin Invest 109:787-96. 2002..These results indicate that TGF-beta1 is an important mediator of the hypertrophic growth response of the heart to Ang II...
- Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heartEsther E Creemers
Heart Failure Research Center, Academic Medical Center, Meibergdreef 15, Room L2 108 3, 1105 AZ Amsterdam, The Netherlands
Cardiovasc Res 89:265-72. 2011..Finally, we will discuss the recent discovery that miRNAs importantly regulate cardiac fibrosis...
- MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult heartsScot J Matkovich
Center for Pharmacogenomics, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
Circ Res 106:166-75. 2010..Because miR-133a levels decrease during reactive cardiac hypertrophy, some have considered that restoring miR-133a levels could suppress hypertrophic remodeling...
- The role of natriuretic peptides in cardioprotectionToshio Nishikimi
Department of Hypertension and Cardiorenal Medicine, Dokkyo University School of Medicine, Mibu, Tochigi 321 0293, Japan
Cardiovasc Res 69:318-28. 2006..In a clinical setting, human recombinant ANP and BNP may be used for a therapy of heart failure; however, further evaluation is required in the future...
- A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophyTakaaki Senbonmatsu
Departments of Biochemistry, Pharmacology, Pathology and Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 0146, USA
EMBO J 22:6471-82. 2003..PLZF is expressed robustly in the heart in contrast to many other tissues. This cardiac selective pathway involving AT(2), PLZF and p85 alpha PI3K may explain the absence of a cardiac hypertrophic response in AT(2) gene-deleted mice...
- Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failureDao Fu Dai
Department of Pathology, University of Washington, 1959 Pacific Ave NE, Seattle, WA 98195, USA
Circ Res 108:837-46. 2011..Mitochondrial dysfunction has been implicated in several cardiovascular diseases; however, the roles of mitochondrial oxidative stress and DNA damage in hypertensive cardiomyopathy are not well understood...
- Sodium-hydrogen exchanger, cardiac overload, and myocardial hypertrophyHoracio E Cingolani
Centro de Investigaciones Cardiovasculares, Facultad de Ciencias Medicas, Universidad Nacional de La Plata, Calle 60 y 120, 1900 La Plata, Argentina
Circulation 115:1090-100. 2007
- Role of oxidative stress in cardiac hypertrophy and remodelingEiki Takimoto
Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21205, USA
Hypertension 49:241-8. 2007
- Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7)Justin L Grobe
Department of Pharmacodynamics, University of Florida, Gainesville, FL 32610 0487, USA
Am J Physiol Heart Circ Physiol 292:H736-42. 2007....
- Maintenance of cardiac energy metabolism by histone deacetylase 3 in miceRusty L Montgomery
Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
J Clin Invest 118:3588-97. 2008..These findings reveal a unique role for Hdac3 in maintenance of cardiac function and regulation of myocardial energy metabolism...
- Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagyDian J Cao
Department of Internal Medicine Cardiology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
Proc Natl Acad Sci U S A 108:4123-8. 2011..Together, these data implicate autophagy as an obligatory element in pathological cardiac remodeling and point to HDAC1/2 as required effectors. Also, these data reveal autophagy as a previously unknown target of HDAC inhibitor therapy...
- miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophyZhiqiang Lin
Division of Cardiovascular Research, National Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China
Proc Natl Acad Sci U S A 106:12103-8. 2009..Its translation could be suppressed by miR-23a. Our data provide a model in which the miRNA expression is regulated by the hypertrophic transcriptional factor...
- Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic miceS Engelhardt
Institut fur Pharmakologie, Universitat Wurzburg, Versbacher Strasse 9, 97078 Wurzburg, Germany
Proc Natl Acad Sci U S A 96:7059-64. 1999..We conclude that overexpression of beta1-adrenergic receptors in the heart may lead to a short-lived improvement of cardiac function, but that increased beta1-adrenergic receptor signalling is ultimately detrimental...
- Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic bandingHae Jin Kee
Department of Pharmacology, Research Institute of Medical Sciences and Medical Research Center for Gene Regulation, Chonnam National University Medical School, Gwangju, South Korea
Circulation 113:51-9. 2006..We tested the effects of several HDAC inhibitors, including a class I HDAC-selective inhibitor, SK-7041, on cardiac hypertrophy induced by angiotensin II (Ang II) treatment or aortic banding (AB)...
- Molecular regulation of cardiac hypertrophySean P Barry
Medical Molecular Biology Unit, Institute of Child Health, University College London, 30 Guilford Street, London WC1N IEH, United Kingdom
Int J Biochem Cell Biol 40:2023-39. 2008..The challenge will be translating this knowledge into potential pharmacological therapies for the treatment of cardiac pathologies...
- Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5Rick B Vega
Department of Molecular Biology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9148, USA
Mol Cell Biol 24:8374-85. 2004....
- GATA transcription factors in the developing and adult heartSampsa Pikkarainen
Department of Pharmacology and Toxicology, Faculty of Medicine, Biocenter Oulu, University of Oulu, P O Box 5000, FIN 90014 Oulu, Finland
Cardiovasc Res 63:196-207. 2004..The present review discusses current evidence of the role and regulation of GATA transcription factors in the heart, with an emphasis in the GATA-4 and development of cardiac hypertrophy...
- Measurement of cardiac function using pressure-volume conductance catheter technique in mice and ratsPal Pacher
Section on Oxidative Stress Tissue Injury, Laboratories of Physiological Studies, National Institutes of Health NIAAA, 5625 Fishers Lane, MSC 9413, Bethesda, Maryland 20892 9413, USA
Nat Protoc 3:1422-34. 2008..The completion of the protocol takes 1-4 h (depending on the experimental design/end points)...
- Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heartE D Abel
Division of Endocrinology and Metabolism, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
J Clin Invest 104:1703-14. 1999..Basal and isoproterenol-stimulated isovolumic contractile performance was preserved. Thus, selective ablation of GLUT4 in the heart initiates a series of events that results in compensated cardiac hypertrophy...
- Adiponectin-mediated modulation of hypertrophic signals in the heartRei Shibata
Molecular Cardiology Whitaker Cardiovascular Institute, Boston University School of Medicine, 715 Albany Street, W611, Boston, Massachusetts 02118, USA
Nat Med 10:1384-9. 2004..Adiponectin may have utility for the treatment of hypertrophic cardiomyopathy associated with diabetes and other obesity-related diseases...
- Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surfaceTimothy A McKinsey
Gilead Colorado, Inc, 7575 West 103rd Avenue, Westminster, Colorado 80021, USA
Nat Rev Drug Discov 6:617-35. 2007....
- Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathwaysMichael A Crackower
IMBA, Institute for Molecular Biotechnology of the Austrian Academy of Sciences, c o Dr Bohr Gasse 7, A 1030, Vienna, Austria
Cell 110:737-49. 2002..These data show that PTEN has an important in vivo role in cardiomyocyte hypertrophy and GPCR signaling and identify a function for the PTEN-PI3Kgamma pathway in the modulation of heart muscle contractility...
- Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtypeJ Sadoshima
Molecular Medicine Division, Beth Israel Hospital, Boston, Mass 02215
Circ Res 73:413-23. 1993....
- Molecular targets and regulators of cardiac hypertrophyAgrawal Rohini
JSS College of Pharmacy 1 Off campus of JSS University, Mysore, Ooty, Tamilnadu, India ahuja
Pharmacol Res 61:269-80. 2010..The purpose of this review is to provide the current knowledge about the molecular pathogenesis of cardiac hypertrophy, with special emphasis on novel researches and investigations...
- Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascadeScott E Woodman
Department of Molecular Pharmacology, Division of Hormone Dependent Tumor Biology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
J Biol Chem 277:38988-97. 2002..Taken together, our data argue that loss of Cav-3 expression is sufficient to induce a molecular program leading to cardiac myocyte hypertrophy and cardiomyopathy...
- Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophyBenjamin J Wilkins
Division of Molecular Cardiovascular Biology, Department of Pediatrics, Children s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, Ohio 45229 3039, USA
Circ Res 94:110-8. 2004....
- Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failureMahesh P Gupta
Department of Surgery, Basic Science Division, MC5040, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, USA
J Mol Cell Cardiol 43:388-403. 2007..This article reviews the published data describing the role of myosin isoforms in the heart and highlighting the importance of various factors shown to influence myosin isofrom shift during physiology and disease states of the heart...
- Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in ratsRobson A S Santos
Laboratory of Hypertension, Department of Physiology and Biophysics, Biological Sciences Institute, Federal University of Minas Gerais, Belo Horizonte, MG, 31270 901 Brazil
Physiol Genomics 17:292-9. 2004..These results support a cardioprotective role for circulating ANG-(1-7) and provide a novel tool for evaluating the functional role of ANG-(1-7)...
- TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophyNaoya Onohara
Department of Pharmacology and Toxicology, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi ku, Fukuoka
EMBO J 25:5305-16. 2006..These data suggest that DAG-induced Ca(2+) signaling pathway through TRPC3 and TRPC6 is essential for Ang II-induced NFAT activation and cardiac hypertrophy...
- GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activationJian Xu
Department of Pediatrics, University of Cincinnati, Division of Molecular Cardiovascular Biology, Children s Hospital Medical Center, Ohio 45229 3039, USA
Circ Res 98:342-50. 2006..These results identify GDF15 as a novel autocrine/endocrine factor that antagonizes the hypertrophic response and loss of ventricular performance, possibly through a mechanism involving SMAD proteins...
- Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivoNicole H Purcell
Department of Pediatrics, Cincinnati Children s Hospital Medical Center, University of Cincinnati, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
Proc Natl Acad Sci U S A 104:14074-9. 2007..Thus, ERK1/2 signaling is not required for mediating physiologic or pathologic cardiac hypertrophy in vivo, although it does play a protective role in response to pathologic stimuli...
- Rapamycin attenuates load-induced cardiac hypertrophy in miceTetsuo Shioi
Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, Mass 02215, USA
Circulation 107:1664-70. 2003..The mammalian target of rapamycin (mTOR) is a component of the insulin-phosphoinositide 3-kinase pathway, which is known to play a critical role in the determination of cell, organ, and body size...
- The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literatureHannerieke M P Van den Hout
Divison of Metabolic Diseases and Genetics, Department of Pediatrics, Erasmus Medical Center Sophia Children s Hospital, Rotterdam, The Netherlands
Pediatrics 112:332-40. 2003..Current developments toward enzyme replacement therapy are promising. The aim of our study is to delineate the natural course of the disease to verify endpoints of clinical studies...
- Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous systemMatthew C Zimmerman
Department of Anatomy and Cell Biology, The University of Iowa, Roy J and Lucille A Carver College of Medicine, Iowa City 52242, USA
Circ Res 95:210-6. 2004..These data suggest that increased intracellular O2*- production in the SFO is critical in the development of Ang II-induced hypertension...
- Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophyYongli Kong
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390 8573, USA
Circulation 113:2579-88. 2006..Thus, HDAC inhibitors hold promise as potential therapeutic agents in hypertrophic heart disease...
- Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overloadJulie R McMullen
Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, Mass 02215, USA
Circulation 109:3050-5. 2004..We recently reported that administration of rapamycin before exposure to ascending aortic constriction significantly attenuated the load-induced increase in heart weight by approximately 70%...
- Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophyDe Li Dong
Department of Pharmacology, Harbin Medical University, Baojian Rd 157, Harbin 150081, Heilongjiang Province, People s Republic of China
Hypertension 55:946-52. 2010..Our data show that reciprocal repression between miR-133 and calcineurin regulates cardiac hypertrophy...
- Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophyLennart Suckau
Department of Cardiology and Pneumology, Charite University Medicine Berlin, Germany
Circulation 119:1241-52. 2009..Whereas gene therapy rests on recombinant protein expression as its basic principle, RNAi therapy uses regulatory RNAs to achieve its effect...
- Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1)Stephan Rosenkranz
Klinik III fur Innere Medizin, Universitat zu Koln, 50924 Köln, Germany
Am J Physiol Heart Circ Physiol 283:H1253-62. 2002....
- Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failureJulie R McMullen
Baker Heart Research Institute, Melbourne, Victoria 8008, Australia
Clin Exp Pharmacol Physiol 34:255-62. 2007..4. The present review discusses the possibility of targeting cardioprotective signalling pathways and genes activated in the athlete's heart to treat or prevent heart failure...
- Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complexHui Hua Li
Carolina Cardiovascular Biology Center, University of North Carolina at Chapel Hill, NC 27599 7126, USA
J Clin Invest 114:1058-71. 2004....
- Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin IIK Nakamura
Department of Cardiovascular Medicine, Okayama University Medical School, Japan
Circulation 98:794-9. 1998..Signal transduction pathways of those factors are implicated in reactive oxygen intermediates (ROIs). Therefore, we hypothesized that TNF-alpha and Ang II might cause myocyte hypertrophy via the generation of ROIs...
- HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive ratsJeffrey P Cardinale
Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA
Hypertension 56:437-44. 2010....
- Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overloadHongliang Li
Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China
Proc Natl Acad Sci U S A 107:13818-23. 2010..These studies indicate that Rgs5 protein is a crucial component of the signaling pathway involved in cardiac remodeling and heart failure...
- Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitorsChristopher L Antos
Department of Molecular Biology, The University of Texas, Southwestern Medical Center at Dallas, Dallas, Texas 75390 9148, USA
J Biol Chem 278:28930-7. 2003..HDAC inhibitors are currently being tested in clinical trials as anti-cancer agents. Our results suggest that these inhibitors may also hold promising clinical value as therapeutics for cardiac hypertrophy and heart failure...
- Cardiac hypertrophy and thyroid hormone signalingWolfgang Dillmann
University of California, San Diego, USA
Heart Fail Rev 15:125-32. 2010..The failing heart may develop a "hypothyroid" status contributing to diminished cardiac contractile function...
- Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failureTomoe Y Nakamura
Department of Molecular Physiology, National Cardiovascular Center Research Institute, Suita, Osaka 565 8565, Japan
Circ Res 103:891-9. 2008..We conclude that activation of NHE1 is sufficient to initiate cardiac hypertrophy and heart failure mainly through activation of CaMKII-histone deacetylase pathway...
- NFATc4 is negatively regulated in miR-133a-mediated cardiomyocyte hypertrophic repressionQi Li
Center for Molecular Development and Disease, Institute of Biosciences and Technology, Texas A and M Health Science Center, 2121 W Holcombe Blvd, Houston, TX 77030, USA
Am J Physiol Heart Circ Physiol 298:H1340-7. 2010..Application of miR-133a had no apparent effect on NFATc4 nuclear localization. We conclude that the negative regulation of NFATc4 expression contributes to miR-133a-mediated hypertrophic repression...
- Protein kinase cascades in the regulation of cardiac hypertrophyGerald W Dorn
Heart and Vascular Center, Medical Center, University of Cincinnati, Cincinnati, Ohio 45267 0542, USA
J Clin Invest 115:527-37. 2005..Here we review recent developments in the area of these cardiotrophic kinases, highlighting the utility of animal models that are helping to identify molecular targets in the human condition...
- Roles of cardiac transcription factors in cardiac hypertrophyHiroshi Akazawa
Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, 1 8 1 Inohana, Chuo Ku, Chiba 260 8670, Japan
Circ Res 92:1079-88. 2003..In this review, the regulation of a cardiac gene program by cardiac transcription factors is summarized, with an emphasis on their potential role in the generation of cardiac hypertrophy...
- The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic miceO F Bueno
Department of Pediatrics, University of Cincinnati, Division of Molecular Cardiovascular Biology, Children s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229 3039, USA
EMBO J 19:6341-50. 2000..The results of the present study indicate that the MEK1-ERK1/2 signaling pathway stimulates a physiologic hypertrophy response associated with augmented cardiac function and partial resistance to apoptotsis...
- Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophyQing Li
Key Laboratory of Stem Cell Biology and Laboratory of Nucleic Acid and Molecular Medicine, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
J Cell Sci 123:2444-52. 2010....
- Cardiac hypertrophy is not a required compensatory response to short-term pressure overloadJ A Hill
Division of Cardiovascular Diseases, Department of Internal Medicine, Department of Veterans Affairs, University of Iowa College of Medicine, Iowa City 52242 1081, USA
Circulation 101:2863-9. 2000..Cardiac hypertrophy is considered a necessary compensatory response to sustained elevations of left ventricular (LV) wall stress...
- Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodelingPaula A da Costa Martins
Department of Medical Physiology, University Medical Center Utrecht, Utrecht, Netherlands
Circulation 118:1567-76. 2008..Dicer, an RNAse III endonuclease critical for processing of pre-microRNAs (miRNAs) into mature 22-nucleotide miRNAs, has proven a useful target to dissect the significance of miRNAs biogenesis in mammalian biology...
- Sympathetic alpha(2)-adrenoceptors prevent cardiac hypertrophy and fibrosis in mice at baseline but not after chronic pressure overloadRalf Gilsbach
Institute of Experimental and Clinical Pharmacology and Toxicology, University of Freiburg, Albertstrasse 25, Freiburg 79104, Germany
Cardiovasc Res 86:432-42. 2010..The aim of this study was to define the physiological and pharmacological role of alpha(2A)-adrenoceptors in adrenergic vs. non-adrenergic cells at baseline and during sympathetic stress...
- Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophyJaya Krishnan
Institute of Cell Biology and Competence Center for Systems Physiology and Metabolic Diseases, ETH Zurich, Zurich, Switzerland
Cell Metab 9:512-24. 2009..We propose a model in which activation of the HIF1alpha-PPARgamma axis by pathologic stress underlies key changes in cell metabolism that are characteristic of and contribute to common forms of heart disease...
- Akt and MAPK signaling mediate pregnancy-induced cardiac adaptationEunhee Chung
Department of Molecular, Cellular, and Developmental Biology and Biofrontiers Institute, University of Colorado, Boulder, Colorado 80309 0347, USA
J Appl Physiol (1985) 112:1564-75. 2012..Inhibition of MEK1 effectively blocked progesterone-induced cellular hypertrophy. Taken together, our study demonstrates that pregnancy-induced cardiac hypertrophy is mediated by activation of Akt and ERK1/2 pathways...
- Akt signaling mediates postnatal heart growth in response to insulin and nutritional statusIchiro Shiojima
Molecular Cardiology Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts 02118, USA
J Biol Chem 277:37670-7. 2002....
- Activation of IP prostanoid receptors prevents cardiomyocyte hypertrophy via cAMP-dependent signalingRebecca H Ritchie
Howard Florey Institute, Melbourne, Victoria 8008, Australia
Am J Physiol Heart Circ Physiol 287:H1179-85. 2004..01, n = 5). Activation of IP receptors thus represents a novel approach to prevention of hypertrophy, and this effect is linked to cAMP-dependent signaling...
- Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studiesOleg Tarnavski
Cardiovascular Research Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
Physiol Genomics 16:349-60. 2004..The cardiac surgical techniques described have been, and will continue to be, important for elucidating the molecular mechanisms of cardiac hypertrophy and failure with high-throughput technology...
- A new type of ERK1/2 autophosphorylation causes cardiac hypertrophyKristina Lorenz
Institute of Pharmacology and Toxicology, University of Wurzburg, Versbacher Strasse 9, Wurzburg, Germany
Nat Med 15:75-83. 2009..We propose that specific phosphorylation events on ERK1/2 integrate differing upstream signals (Raf1-MEK1/2 or G protein-coupled receptor-G(q)) to induce cardiac hypertrophy...
- Overexpression of junctate induces cardiac hypertrophy and arrhythmia via altered calcium handlingChang Soo Hong
Department of Biological Science, College of Natural Sciences, Daegu University, Gyeongsan, South Korea
J Mol Cell Cardiol 44:672-82. 2008..Junctate-1 in the heart is closely linked to the homeostasis of E-C coupling proteins and a sustained increase of junctate-1 expression leads to a severe cardiac remodeling and arrhythmias...
- Dysregulation of the TSC-mTOR pathway in human diseaseKen Inoki
Life Sciences Institute, University of Michigan, Ann Arbor, Michigan 48109, USA
Nat Genet 37:19-24. 2005....
- The expression of mRNA of cytokines and of extracellular matrix proteins in triiodothyronine-treated rat heartsBarbara Ziegelhöffer-Mihalovicová
Carl Ludwig Institute of Physiology, University of Leipzig, Leipzig, Germany
Mol Cell Biochem 247:61-8. 2003..The moderate increase in mRNA for ECMP and MMP may be attributed more to the increasing mass of the ventricles with the accompanying remodelling of the ECM than to increased fibrosis...
- Increased expression and intramitochondrial translocation of cyclophilin-D associates with increased vulnerability of the permeability transition pore to stress-induced opening during compensated ventricular hypertrophyJimmy Matas
Département de Kinésiologie, Universite de Montreal, C P 6128, Succursale Centre Ville, Montreal, Quebec, Canada H3C 3J7
J Mol Cell Cardiol 46:420-30. 2009....
- Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMPAnke C Rosenkranz
Howard Florey Institute, C The University of Melbourne, Parkville, VIC 3010, Australia
Cardiovasc Res 57:515-22. 2003..However, whether this effect is retained in the adult phenotype or if other members of the natriuretic peptide family exhibit similar antihypertrophic properties, has not been elucidated...
- The transcriptional coactivator CAMTA2 stimulates cardiac growth by opposing class II histone deacetylasesKunhua Song
Department of Molecular Biology, The University of Texas Southwestern Medical Center at Dallas, 6000 Harry Hines Blvd, Dallas, TX 75390, USA
Cell 125:453-66. 2006..These findings reveal a transcriptional regulatory mechanism that modulates cardiac growth and gene expression by linking hypertrophic signals to the cardiac genome...
- RGS4 reduces contractile dysfunction and hypertrophic gene induction in Galpha q overexpressing miceJ H Rogers
Center for Cardiovascular Research, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
J Mol Cell Cardiol 33:209-18. 2001..These studies establish for the first time a role for RGS4 as a GAP for Galpha q in the in vivo heart, and demonstrate that its regulated expression can have pathophysiologic consequences...
- TRPC channels are necessary mediators of pathologic cardiac hypertrophyXu Wu
Department of Pediatrics, Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229, USA
Proc Natl Acad Sci U S A 107:7000-5. 2010..Thus, TRPC channels are necessary mediators of pathologic cardiac hypertrophy, in part through a calcineurin-NFAT signaling pathway...
- Signaling mechanisms in thyroid hormone-induced cardiac hypertrophyKaie Ojamaa
The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY 11030, USA
Vascul Pharmacol 52:113-9. 2010..The present review examines these molecular mechanisms and intracellular signaling pathways activated in thyroid hormone-induced cardiac hypertrophy that support its therapeutic potential in the treatment of heart disease...
- Mammalian target of rapamycin is a critical regulator of cardiac hypertrophy in spontaneously hypertensive ratsWill Soesanto
College of Health, University of Utah, Salt Lake City, UT 84112, USA
Hypertension 54:1321-7. 2009..These data show that mammalian target of rapamycin is required for the development of cardiac hypertrophy evoked by rising blood pressure in SHRs...
- Differential regulation of proteasome function in isoproterenol-induced cardiac hypertrophyOliver Drews
School of Medicine, University of California Los Angeles, 675 Charles E Young Drive, Los Angeles, CA 90095 1760, USA
Circ Res 107:1094-101. 2010..Our recent investigations identified heterogeneous subpopulations of proteasome complexes in the heart and implicated multiple mechanisms for their regulation...
- S100A4 is upregulated in injured myocardium and promotes growth and survival of cardiac myocytesMikael Schneider
The Laboratory of Molecular and Cellular Cardiology, The Danish National Research Foundation Centre for Cardiac Arrhythmia, Department of Medicine B, H S Rigshospitalet, Copenhagen University Hospital, Denmark
Cardiovasc Res 75:40-50. 2007..We therefore hypothesized that S100A4 could play a supportive role in the injured heart...
- The nonpeptide AVE0991 attenuates myocardial hypertrophy as induced by angiotensin II through downregulation of transforming growth factor-beta1/Smad2 expressionJian gui He
Department of Cardiology, First Affiliated Hospital of Sun Yat sen University, Guangzhou, PR China
Heart Vessels 25:438-43. 2010..These results suggested that AVE0991 prevented AngII-inducing myocardial hypertrophy in a dose-dependent fashion, a process that may be associated with the inhibition of TGF-beta1/Smad2 signaling...
- L-Thyroxine activates Akt signaling in the heartJames A Kuzman
School of Medicine, University of South Dakota, Cardiovascular Research Institute South Dakota Health Research Foundation, 1100 East 21st Street, Sioux Falls, SD 57105, USA
J Mol Cell Cardiol 39:251-8. 2005..In conclusion, activation of the Akt signaling pathway may contribute to the effects of TH on the heart. While this pathway is clearly activated, further work is needed to determine whether this is via a genomic or non-genomic mechanism...
- Mitochondrial adaptations to physiological vs. pathological cardiac hypertrophyE Dale Abel
Division of Endocrinology, Metabolism and Diabetes, and Program in Molecular Medicine, University of Utah School of Medicine, 15 North 2030 East, Bldg 533, Rm 3110B, Salt Lake City, UT 84112, USA
Cardiovasc Res 90:234-42. 2011..We suggest that mitochondrial adaptations to pathological and physiological hypertrophy are distinct, and we shall review potential mechanisms that might account for these differences...
- Simvastatin inhibits angiotensin II-induced cardiac cell hypertrophy: role of Homer 1aWan Gang Guo
Department of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi an, China
Clin Exp Pharmacol Physiol 37:40-5. 2010..5. These results suggest a possible role for Homer 1a in inhibiting cardiac hypertrophy perhaps in part through inhibition of ERK1/2 activation...
- Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitroJ Sadoshima
Molecular Medicine Division, Beth Israel Hospital, Boston, Massachusetts
Cell 75:977-84. 1993..The results not only provide direct evidence for the autocrine mechanism in load-induced growth of cardiac muscle cells, but also define the pathophysiological role of the local (cardiac) renin-angiotensin system...
- Requirement of nuclear factor of activated T-cells in calcineurin-mediated cardiomyocyte hypertrophyEva van Rooij
Department of Cardiology, Cardiovascular Research Institute Maastricht, University Hospital, P Debyelaan 25, The Netherlands
J Biol Chem 277:48617-26. 2002..These results indicate that multiple NFAT isoforms are expressed in cardiomyocytes where they function as necessary transducers of calcineurin in facilitating cardiomyocyte hypertrophy...
- 2005 NNFF Consortium for NF1, NF2 and SchwannomatosisJonathan Epstein; Fiscal Year: 2005....
- Identification and Validation of Alcohol Biomarker Signatures by ProteomicsEmanuel Rubin; Fiscal Year: 2010..Early diagnosis of this condition by specific biomarkers will offer the opportunity for treatment and prevention of heart enlargement, congestive heart failure and death. ..
- Nuclear magnetic Tirho relaxation in acute and chronic myocardial infarctionsWalter R T Witschey; Fiscal Year: 2013..This training will prepare Dr. Witschey to achieve his career goals to advance our understanding and treatment of cardiac disease through novel and interdisciplinary techniques combined with basic science research. ..
- EFFECT OF CARBON MONOXIDE ON THE DEVELOPING HEARTDavid Penney; Fiscal Year: 1980..Studies in my laboratory and by others show that cardiomegaly is more dramatic in the young than the old...
- HIGH-RESOLUTION IMAGE PROCESSING WORKSTATIONKunio Doi; Fiscal Year: 1992..detection of various abnormalities in the chest, due to interstitial disease, lung cancer, pneumothorax, and cardiomegaly. The mammography project of Dr. Giger, in collaboration with Drs...
- Metabolic enzyme activity mediating myocardial stunningE Lewandowski; Fiscal Year: 2006..unreadable] [unreadable] [unreadable]..
- Calpains as Mediators of Cardiac Ischemic InjuryGerald W Dorn; Fiscal Year: 2010..Collectively, these studies will apply state-of-the-art techniques for in vivo genetic manipulation, microphysiologic analysis, and biochemical assessment to achieve insight into the roles of myocardial calpains in health and disease. ..
- CALMODULIN KINASE II AND EARLY AFTERDEPOLARIZATIONSMark Anderson; Fiscal Year: 2007..unreadable] [unreadable] Understanding these molecular mechanisms for Ca2+/CaM-dependent ICa facilitation will likely be necessary to develop improved therapies for TdP. [unreadable] [unreadable]..
- MAGNETIC RESONANCE CARDIAC C13FLUX AND METABOLIC RATEE Lewandowski; Fiscal Year: 2001..The long range objective is the ultimate use of C13 NMR to assess the activity and expression of these mitochondrial proteins that regulate metabolic flux in intact and in vivo organs during development and disease. ..
- PHOSPHOLIPASE C AND CARDIAC HYPERTROPHYGERALD DORN; Fiscal Year: 2005..abstract_text> ..
- PAX3 REGULATION OF CARDIAC CONOTRUNCAL DEVELOPMENTJonathan Epstein; Fiscal Year: 2008..Aim 3 examines the role of neural crest during development of the conduction system, and specifically examines Pax3 regulation of DCT. [unreadable] [unreadable]..
- Molecular basis of vascular heterogenity and functionJonathan Epstein; Fiscal Year: 2008..abstract_text> ..
- LBX2 AND UROGENITAL DEVELOPMENTJonathan Epstein; Fiscal Year: 2002....
- Proteome Mapping of Heart Failure in AgingMARVIN BOLUYT; Fiscal Year: 2005..Identification of proteins involved in aldosterone signaling will lead to the development of new hypotheses for future grant proposals addressing their roles in the development of heart failure in the elderly. ..
- Role of Acetaldehyde in Alcoholic CardiomyopathyJun Ren; Fiscal Year: 2008..Our long-term goal is to establish the toxic mechanism of acetaldehyde in the development of alcoholic cardiomyopathy so that prevention and treatment can be optimized [unreadable] [unreadable]..
- Oxidative Stress and Heart Failure by Copper RestrictionY James Kang; Fiscal Year: 2010..Therefore, Cu supplementation is not an appropriate approach to rescue diabetic cardiomyopathy. ..
- Apoptosis inducing factor in cardiac apoptosisPeter M Kang; Fiscal Year: 2010..We will then explore a mechanism and a strategy for inhibiting AIF activation using PARP-1 inhibition in I/R-induced cardiac apoptosis in vivo. ..
- PHOSPHOINOSITIDE-3 KINASE IN CARDIAC HYPERTROPHYPeter Kang; Fiscal Year: 2004..These studies will lead to a better understanding of the role of the PI3K pathway in determining the heart and myocyte size in physiological and pathological conditions in vivo. ..
- METALLOTHIONEIN AND ADRIAMYCIN CARDIOTOXICITYY Kang; Fiscal Year: 2006..abstract_text> ..
- Control of Cardiac Gene Expression Through Regulated Transcriptional CoactivatorsEric N Olson; Fiscal Year: 2010..abstract_text> ..
- Calcineurin-Mediated Regulation of Cardiac Ca2+ ChannelJoseph Hill; Fiscal Year: 2009..In Aim 4, we will determine whether the mechanisms of calcineurin regulation of Ca2+ channel expression and function examined in Aims 1-3 occur in a clinically relevant, in vivo model of hypertrophy. ..
- Cardiac Hypertrophy Due to Oxidative Stress InsulinThunder Jalili; Fiscal Year: 2006..unreadable] [unreadable] [unreadable]..
- SUMMER RESEARCH PROGRAM FOR MINORITY MEDICAL STUDENTSDonald Menick; Fiscal Year: 2008....
- Developmental regulation of cardiac gene expressionAnthony Azakie; Fiscal Year: 2007..An understanding of the transcriptional mechanisms that control cardiogenesis may also elucidate the molecular pathogenesis of various congenital heart defects and cardiomyopathies. ..
- Glucolipotoxicity and Cardiac Dysfunction in ObesityHeinrich Taegtmeyer; Fiscal Year: 2007..abstract_text> ..
- Role of Caspase-9 in HeartPeter Kang; Fiscal Year: 2005..Thus, the cardiac specific knockout of caspase-9 using Cre-loxP technology allows us to examine the tissue-specific role of capase-9 in adult animal. ..
- DYNAMICS OF MYOCARDIAL GLUCOSE METABOLISMHeinrich Taegtmeyer; Fiscal Year: 2002....
- TRANSCRIPTIONAL CONTROL OF CARDIAC HYPERTROPHYEric Olson; Fiscal Year: 2002..End of Abstract) ..
- IGF-1, Oxidative Stress and Cardiovascular AgingJun Ren; Fiscal Year: 2002..Our long-term goal is to establish the causal link among IGF-1 deficiency, enhanced oxidative damage and ventricular dysfunction in the progression of cardiovascular aging so that hormonal or antioxidant therapy can be optimized...
- Laser Microdissection SystemEric Olson; Fiscal Year: 2004....
- MOLECULAR AND CELLULAR MECHANISMS OF HEART DISEASEHeinrich Taegtmeyer; Fiscal Year: 2003..abstract_text> ..
- Signaling Pathways Mediating NCX1 ExpressionDonald Menick; Fiscal Year: 2004..The therapeutic modulation of these targets may potentially reverse the endpoints associated with the disease phenotype. ..
- Gordon Research Conference:Cardiac Regulatory MechanismsR Solaro; Fiscal Year: 2002..Much of the time of the meeting is devoted to debates and discussion. Presentations of late breaking science from young investigator will be added from the posters submitted to the meeting. ..
- ISOLATED DIASTOLIC DYSFUNCTIONMARGARET REDFIELD; Fiscal Year: 2008....
- TRANSCRIPTIONAL CONTROL OF CARDIOVASCULAR PATHOLOGYKenneth Walsh; Fiscal Year: 2001....
- Mechanisms of AngiogenesisKenneth Walsh; Fiscal Year: 2009..LKB1-knockout mice will be created and their baseline phenotype will be assessed. Endothelial LKB1-deficient mice will be subjected to ischemic stresses and vascular responses will be evaluated. ..
- Vitamin D and Cardiovascular DiseaseRavi Thadhani; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- COLLABORATIVE R01Rhonda Bassel Duby; Fiscal Year: 2002..In this iterative manner, the investigators expect to gain knowledge that ultimately will foster the development of cell transplantation strategies to promote myocardial repair in human patients afflicted with heart failure. ..
- SPARC Modulates Extracellular Matrix Dynamics in SkinAMY BRADSHAW; Fiscal Year: 2004....
- MOLECULAR PHYSIOLOGY OF MYOCARDIAL TROPONIN I VARIANTSAnne Murphy; Fiscal Year: 2008..In the long-term this will assist in the development of novel therapies which address the correction of myofilament defects. ..
- MECHANISMS OF DILATED CARDIOMYOPATHY IN CREB A133Guy Reed; Fiscal Year: 2002..Taken together the results of this work should provide us with important new insights into the molecular mechanisms underlying human DC and CHF. ..
- NATRIURETIC PEPTIDE INHIBITS VEGF SYNTHESIS AND ACTIONSELLIS LEVIN; Fiscal Year: 2002..These will be shown by protein synthesis and kinase activity studies, in cells transfected with dominant negative SEK-1 (JNK kinase) and JNK-1, or PD98059 (Mek inhibitor). ..
- The Effect of Statins on Skeletal Muscle FunctionPAUL DAVIS THOMPSON; Fiscal Year: 2010....
- PO2 MODULATION OF NO AND ET1 IN PULMONARY HYPERTENSIONKaren Fagan; Fiscal Year: 2002..Improved understanding of these endogenous vasoregulatory substances, their interactions with one another, and the effect of modest hypoxia in vivo are the major goals of this proposal and may lead to new therapeutic options. ..
- ROLES FOR P38 MAP KINASES IN CARDIAC MYOCYTE GROWTHCHRISTOPHER GLEMBOTSKI; Fiscal Year: 2003..abstract_text> ..
- RHOA KINASES IN CARDIAC HYPERTROPHYRobert Schwartz; Fiscal Year: 2003..abstract_text> ..
- GENETIC ANALYSIS OF CARDIAC TERMINAL DIFFERENTIATIONW MacLellan; Fiscal Year: 2003..This first RO1 proposes to further define the role of PRI-1 in cardiac myocyte differentiation and elucidate its biochemical properties. ..
- SYSTOLIC CARDIAC FUNCTION IN OBESITY AND EXERCISEJOAN CARROLL; Fiscal Year: 2004..Because such a large segment of the American population is overweight or obese, the knowledge and insight gained from these studies can have far-reaching effects. ..
- ANDROGENS, LIPIDS, INSULIN AND HYPERTENSIVE PREGNANCIESRavi Thadhani; Fiscal Year: 2005..abstract_text> ..
- Pulse Doppler Ultrasound Imaging SystemJOAN CARROLL; Fiscal Year: 2004..abstract_text> ..
- MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AWGeorge Mansoor; Fiscal Year: 2004..This study will provide information that will be important if clinical trials targeting nocturnal BP are to be designed. ..
- MECHANICAL REGULATION OF DILATED CARDIOMYOPATHYJeffrey Omens; Fiscal Year: 2004..We propose that these regional structural changes accompanies dilatory heart failure, and are mechanisms behind the reduction in fiber shortening and the ability of the wall to thicken during systole. ..
- Osteoblastogenesis in Aortic Valve CalcificationNalini Rajamannan; Fiscal Year: 2006..If hypercholesterolemia stimulates the development of calcification in the aortic valve then the use of medical therapy such as HMG CoA reductase medications may have a role in the medical therapy of calcific aortic stenosis. ..
- Role of H11 kinase in cardiac cell growthChristophe Depre; Fiscal Year: 2007..These experiments will unravel novel mechanisms and signaling pathways of cardiac growth, which may result in new therapeutic avenues for both ischemic heart disease and heart failure. ..
- Regulation of cardiac ion channel function via allosteric modulatorsAndrew Marks; Fiscal Year: 2007..The studies are significant because they may lead to a novel therapeutic approach based on allosteric modulation of RyR that can result in improved therapy for human cardiovascular diseases. ..
- Cardiac KATP Channels in Health and DiseaseAndre Terzic; Fiscal Year: 2007..Thus, this proposal will provide an integrated understanding of cardiac KATP channels in metabolic signal decoding, stress adaptation, and their impact for clinical medicine. ..
- Steroid As Cytoprotectants against Oxidative ToxicityQin Chen; Fiscal Year: 2007..unreadable] [unreadable] [unreadable]..
- ECHOCARDIOGRAPHIC STROKE PREDICTORS IN A TRI-ETHNIC COMMMarco Di Tullio; Fiscal Year: 2003..This study will be the first prospective cohort study to evaluate the role of multiple echocardiographic risk factors for ischemic stroke in a community of whites, blacks and Hispanics living in the same area. ..
- NF-kappaB Signaling Networks in I/R and Late PCW Jones; Fiscal Year: 2007..abstract_text> ..
- Cardiac Contraction-Relaxation CouplingPAULUS JANSSEN; Fiscal Year: 2008....
- Effect of Drugs on Myocardial HypoxiaGarrett Gross; Fiscal Year: 2009..Information gained from these studies will hopefully lead to new therapies to treat patients with ischemic heart disease. ..
- The Role of Microsatellite Instability in CancerHarold Garner; Fiscal Year: 2005..We will also (Aim 3) investigate the effects of these mutations identified in Aim 2 on splicing by correlating them with the results of a quantitative global survey of splicing isoforms. ..
- Functional role of Angiopoietin-2 in diabetic heartJian xiong Chen; Fiscal Year: 2007..unreadable] [unreadable] [unreadable]..